Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review

[1]  Jinhui Tian,et al.  Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies , 2023, Frontiers in Pharmacology.

[2]  G. Scagliotti,et al.  Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Yang Zhang,et al.  Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) , 2022, Cancer communications.

[4]  T. Mok,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ying Cheng,et al.  Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Tsuboi,et al.  Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. , 2022, The Lancet. Oncology.

[7]  G. Yancopoulos,et al.  Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial , 2022, Nature Medicine.

[8]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[9]  D. Planchard,et al.  Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[11]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[12]  Baolan Li,et al.  Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  L. Sequist,et al.  Lung cancer , 2021, The Lancet.

[14]  Baolan Li,et al.  Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Yunpeng Liu,et al.  Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  N. Yang,et al.  Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer , 2021, JAMA oncology.

[17]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[18]  M. Humer,et al.  Clinical outcomes of pancoast tumors treated with trimodality therapy , 2020, Journal of Thoracic Disease.

[19]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[20]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[21]  Arash Salmaninejad,et al.  PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy , 2019, Journal of cellular physiology.

[22]  U. Dafni,et al.  Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. , 2019, Lung cancer.

[23]  F. Askin,et al.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. , 2017, Seminars in cancer biology.

[24]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[25]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.